Frontlight ResearchEarly access
CompletedPhase 2/3
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 150 people enrolled
- Started
- 15 Nov 2022
- Ended
- 25 Jan 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Allopurinol 300 MG
- Atorvastatin 20mg
- Placebo
- Record updated
- 11 August 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Inclusion Criteria
- Age 18 to 75 years old
- Both sex
- Adults with cirrhosis in a stable conditions
Who cannot take part
- Active GIT hemorrhage
- Renal insufficiency (serum creatinine > 2.0 mg/dl)
- Exclusion criteria
- Active SBP
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life.
The 3 groups in the trial
- PLACEBOPlacebo, for comparison
Group1: (Placebo, n=50) who will receive oral placebo tablet once daily FOR 6 MONTHS
- AllopurinolExisting treatment, for comparison
Group 2:(Allopurinol n=50) who will receive oral allopurinol 300 mg daily for 6 months
Treatment: Allopurinol 300 MG
- SimvastatinExisting treatment, for comparison
Group 3: (atorvastatin n=50) who will receive oral atorvastatin 20 mg daily for 6 months
Treatment: Atorvastatin 20mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Potential Role of Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis: A Quadruple Blind Clinical Study
- Record updated
- 11 August 2026